OS Therapies Inc. (OSTX) - Q2 2024 10-Q Summary
Business Context and Reporting Period
Company: OS Therapies Inc.
Reporting Period: Quarter and six months ended June 30, 2024.
Business Overview: A clinical-stage biopharmaceutical company focused on developing treatments for Osteosarcoma and other solid tumors. The company's lead candidates are OST-HER2 (an immunotherapy) and OST-tADC (a tunable antibody-drug conjugate platform).
Capital Status: The company is an Emerging Growth Company and Smaller Reporting Company. As of June 30, 2024, the company had not yet completed its Initial Public Offering (IPO), though it closed the IPO on August 2, 2024, subsequent to the reporting period.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,016,472) | $(4,352,026) |
| Net Loss Available to Common Shareholders | $(3,047,722) | $(4,414,526) |
| Loss Per Share (Basic & Diluted) | $(0.52) | $(0.83) |
| Cash and Cash Equivalents (End of Period) | $94,925 | $49,222 |
| Total Assets | $1,342,221 | $798,082 |
| Total Liabilities | $28,406,158 | $24,814,297 |
| Stockholders' Deficit | $(27,063,937) | $(24,016,215) |
| Operating Cash Flow | $(1,522,920) | $(1,259,238) |
| Financing Cash Flow | $1,578,863 | $1,135,854 |
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by approximately $1.3 million (31%) compared to the prior year period, driven primarily by lower Research & Development (R&D) expenses.
- R&D Expense Reduction: R&D expenses dropped from $1.74 million to $0.76 million. Management attributed this to decreased vendor expenses for the Phase IIb clinical trial and the OST-tADC platform.
- Debt Position: Total liabilities increased by approximately $3.6 million, largely due to the accrual of interest on convertible notes and the recognition of redemption premiums. The company issued additional convertible notes (Group F) and short-term loans during the period.
- Equity Structure: Series A Preferred Stock was converted to Common Stock in February 2024. As of June 30, 2024, no Preferred Stock was outstanding.
- Liquidity: Cash on hand increased from $38,982 at year-end 2023 to $94,925 at June 30, 2024, supported by net proceeds from convertible debt financing.
Outlook, Risks, and Contingencies
- Going Concern: The filing explicitly states that the company has incurred net losses since inception and has negative operating cash flows. These circumstances raise substantial doubt about the company's ability to continue as a going concern without additional capital.
- Capital Needs: The company's ability to continue operations is dependent on obtaining additional capital through public or private financing. Deferred offering costs of $1.18 million were capitalized in anticipation of an IPO.
- Subsequent Event (IPO): On August 2, 2024, the company closed its IPO, selling 1.6 million shares at $4.00 per share for gross proceeds of $6.4 million. All outstanding convertible notes automatically converted into common stock upon the IPO closing.
- Legal Proceedings: An arbitration proceeding was filed by Noble Capital Markets regarding alleged breaches of anti-dilution and tail provisions. The company is actively engaged in settlement negotiations.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2024, due to a lack of segregation of duties and insufficient written policies.
- Contractual Obligations: Significant future milestone payments are owed to Advaxis (up to $22.375 million) and BlinkBio (up to $22.375 million) upon achieving regulatory and sales milestones.
Key Facts for Investor Verification
- Post-IPO Capitalization: Verify the final share count and dilution impact following the August 2, 2024 IPO and the automatic conversion of approximately $19.4 million in convertible debt principal and accrued interest.
- Cash Runway: Confirm the current cash balance post-IPO and the burn rate to assess the runway for clinical trials (OST-HER2 Phase IIb and OST-tADC pre-clinical/IND).
- Debt Conversion Terms: Review the specific conversion prices and share counts issued to different note groups (A through F) to understand the dilution profile relative to the IPO price of $4.00.
- Legal Settlement: Monitor the status of the arbitration with Noble Capital Markets to determine if a settlement will result in additional share issuance or cash outflow.
- Internal Control Remediation: Assess the company's plan to remediate the material weaknesses in internal controls identified in the filing.